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ABSTRACT  1 
Torsades de pointes is a characteristic polymorphic ventricular arrhythmia associated with 2 
delayed ventricular repolarisation as evidenced on the surface electrocardiogram by QT 3 
interval prolongation. It typically occurs in self-limiting bursts, causing dizziness and 4 
syncope, but may occasionally progress to ventricular fibrillation and sudden death. Acquired 5 
long QT syndromes are mainly caused by cardiac disease, electrolyte abnormalities or 6 
exposure to drugs that block rectifying potassium channels, especially IKr.  7 
Management of torsades de pointes or marked QT prolongation includes removal or 8 
correction of precipitants, including discontinuation of culprit drugs, and institution of cardiac 9 
monitoring. Electrolyte abnormalities and hypoxia should be corrected, with potassium 10 
concentrations maintained in the high-normal range. Immediate treatment of torsades de 11 
pointes is by intravenous administration of magnesium sulphate, terminating prolonged 12 
episodes using electrical cardioversion. In refractory cases of recurrent torsades, the 13 
arrhythmia can be suppressed by increasing the underlying heart rate using isoproterenol or 14 
transvenous pacing. Other interventions are rarely needed, but there are case reports of 15 
successful use of lidocaine or phenytoin. Antiarrhythmic drugs that prolong ventricular 16 
repolarisation should be avoided.  17 
Some episodes of torsades de points could be avoided by careful prescribing of QT 18 
prolonging drugs, including an individualised assessment of risks and benefits before use, 19 
performing baseline and periodic electrocardiograms and measurement of electrolytes, 20 
especially during acute illnesses, using the lowest effective dose for the shortest possible 21 
time and avoiding potential drug interactions. These steps are particularly important in those 22 
with underlying repolarisation abnormalities and those who have previously experienced 23 
drug-induced torsades. 24 
25 
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BACKGROUND 1 
It is now half a century since the French cardiologist François Dessertenne published his 2 
original report of a characteristic polymorphic ventricular tachycardia and coined the phrase 3 
‘torsades de pointes’a (TdP) or ‘twisting of the points’ to describe its ECG appearance.(1)  4 
This uncommon arrhythmia characteristically occurs in self-terminating bursts, causing 5 
dizziness or syncope and occasionally convulsions, but can occasionally degenerate into 6 
ventricular fibrillation, resulting in sudden cardiac death. 7 
Torsades occurs when there is delayed ventricular repolarisation with associated triggered 8 
activity due to early afterdepolarisations (EADs). Drug-induced delayed repolarisation 9 
characteristically occurs because of blockade of rectifying potassium channels and is 10 
reflected on the 12 lead ECG by prolongation of the QT, which almost invariably precedes 11 
torsades. EADs occur because of continuing late calcium entry resulting from delayed 12 
inactivation of voltage-gated calcium channels as a consequence of prolonged ventricular 13 
depolarisation.  14 
The QT interval  15 
The QT interval extends from the onset of the QRS complex to the end of the T wave and 16 
reflects the duration of ventricular depolarisation and repolarisation. Factors that affect 17 
depolarisation, such as sodium channel blockade, may prolong the QT interval as a result of 18 
increases in QRS duration. The majority of the QT interval, however, from the J point to the 19 
end of the T wave (the JT interval), reflects ventricular repolarisation and the QT interval is 20 
more sensitive to factors that influence this component.   21 
Prolongation of the QT interval can be congenital (genetic) or acquired.  Congenital long QT 22 
syndromes (cLQTS), not considered in detail in this article, are caused by genetic loss-of-23 
                                                 
a
 The correct orthography is disputed, with several variations used in the literature (including by French 
authors). These include torsades des pointes, torsade de pointes, etc. This article uses Dessertenne’s original 
form - torsades de pointes. 
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function mutations that affect the rectifying potassium channels primarily responsible for 1 
cardiac repolarisation, such as IKr, IKs or IK1, or gain-of-function mutations affecting sodium 2 
or rarely L-type calcium channels.(2) Acquired LQTS (aLQTS) is caused by heart disease, 3 
electrolyte abnormalities and/or exposure to precipitating (‘culprit’) medications, of which a 4 
large number have been implicated (Table 1). These drugs usually delay cardiac 5 
repolarisation by blocking relevant potassium channels, especially IKr, which is encoded by 6 
the gene previously referred to as HERG (the human ether a go go-related gene) but now 7 
termed KCNH2.  The risk of torsades with individual drugs is often not well defined, but is 8 
generally higher for most antiarrhythmic agents (e.g. quinidine, sotalol) than non 9 
cardiovascular drugs; amiodarone is thought to be an exception, carrying a low risk of TdP. 10 
Antiarrhythmics are also used in patients likely to have other risk factors.  11 
Assessing risk 12 
The extent of QT prolongation is one of several important risk factors for the development of 13 
torsades. Clinical use of the QT interval as a biomarker for risk of TdP is, however, 14 
hampered by practical difficulties in measurement in a clinical context. While many modern 15 
ECG machines provide automated measurements of QT interval upon which many clinicians 16 
rely, (3) these are not always accurate, so manual confirmation is essential, especially when 17 
the ECG is abnormal. Manual measurements are, however, often problematic due to 18 
uncertainty over the end of the T wave, especially in patients with repolarization 19 
abnormalities and/or prominent U waves. Indeed variability of measurement amongst 20 
cardiologists and even cardiac electrophysiologists can be worryingly high.(4) 21 
It is also necessary to take account of the heart rate, because the QT interval shortens as 22 
heart rate increases. Although TdP due to aLQTS is uncommon in patients with tachycardia, 23 
accurate assessment of delayed repolarisation is still important because of the risk of TdP in 24 
the event of subsequent bradycardia or pauses. Various formulae are available to provide a 25 
QT interval corrected to a heart rate of 60/min (QTc). The original and still most commonly 26 
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used formula is that of Bazett (QTc = QT/[RR0.5]),(5) but a major limitation is that this over-1 
corrects the QT interval in patients with tachycardia resulting in spurious apparent QTc 2 
prolongation, with the reverse occurring in those with bradycardia. These effects are less 3 
marked with more sophisticated correction formulae such as the Fridericia (QTc = 4 
QT/[RR0.33]) or Framingham [QTc = QT + 0.154(1-RR)] methods.(6) All these formulae, 5 
however, require calculation based on the RR interval and even if the measurement of QT 6 
interval is accurate, this is challenging in a clinical environment. Also, because of individual 7 
variation in the relationship between heart rate and QT interval,(7) no universal formula will 8 
provide an ideal heart rate correction for a specific patient.  9 
Women have, on average, longer QT intervals than men, a difference that emerges around 10 
puberty, and are at higher risk of TdP. Using the Bazett formula, a QTc greater than 450 ms 11 
in a male and 470 ms in a female is considered abnormal in adults.(6, 8) More recently it has 12 
been suggested that the 99th centiles for otherwise healthy adults are used as limits of 13 
normality, 470 ms for males and 480 ms for females.(9) TdP is unusual if the Bazett-QTc is 14 
less than 500 ms, although can occur, especially in those with bradycardia; heart rate 15 
correction is therefore probably unnecessary in those with heart rates below 60 /min. In one 16 
study the average QT and Bazett-QTc intervals preceding drug-induced torsades were 580 17 
and 590 ms respectively. (10) 18 
More recently a heart rate-QT interval nomogram has been described for risk stratification 19 
(Figure 1). This method is attractive because avoids the need for correction formulae and is 20 
based on heart rate rather than RR interval. Because the relationship between QT interval, 21 
heart rate and risk is uncertain in those with more rapid heart rates, an interrupted 22 
nomogram line is used for heart rates above 105 /min. As well as being simple to use, the 23 
heart rate-QT nomogram separates patients who develop TdP from those who do not with 24 
improved sensitivity and specificity compared to the various heart rate correction formulae 25 
described above. (11) 26 
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The QT interval is just one important determinant of the risk of TdP and other risk factors 1 
should also be taken into account when planning patient management. In aLQTS the 2 
arrhythmia is more likely to occur in those with bradycardias or pauses because impairment 3 
of IKr produces a prolonged and often dispersed or variable repolarisation. Ventricular 4 
premature contractions may increase risk because they are associated with compensatory 5 
pauses that predispose to TdP. They may result from early after depolarisations (EADs) 6 
occurring above a certain threshold required to cause triggered activity that can induce 7 
arrhythmia. The arrhythmia is more likely to develop if there is instability of repolarisation as 8 
reflected on the ECG by T/U wave variability, such as T wave alternans or short term 9 
variations in the QT interval. (9, 12) TdP is more common in those with structural heart 10 
diseases, including heart failure, myocardial infarction and left ventricular hypertrophy, as 11 
well as those with cLQTS, which may be concealed. Other risk factors include advanced 12 
age, female sex, alcoholic liver disease, recent conversion from atrial fibrillation, 13 
hypokalaemia, hypomagnesaemia, hypocalcaemia and digoxin or diuretic therapy. High 14 
concentrations or rapid intravenous infusion rates of a QT-prolonging drug increase risk, 15 
such as following overdose or when there is reduced drug elimination due to liver or renal 16 
impairment.(9, 13, 14)  17 
Typically, development of severe QT prolongation or torsades requires several precipitating 18 
factors to occur in combination, to overcome a ‘repolarisation reserve’ generated by the 19 
presence of multiple rectifying potassium channels.(9)  Precipitants of aLQTS exacerbate 20 
repolarisation delay in those with cLQTS, while genetic mutations affecting relevant cardiac 21 
channels have been identified in a proportion of patients with aLQTS.(15, 16) Common 22 
genetic variation may also predispose to aLQTS but investigation has so far proven either 23 
limited or disappointing.(17) Patients receiving culprit drug therapies may remain well and 24 
have a normal ECG until other factors supervene such as electrolyte abnormalities, 25 
bradycardias or pauses, when QT prolongation and TdP may develop (‘late proarrhythmia’).  26 
27 
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Prevention of torsades de pointes 1 
Over the past three decades drug regulatory authorities have taken steps to reduce the risk 2 
of licensed medicines causing TdP and this has resulted in several drugs being removed 3 
from the market or use severely restricted. Drug development now requires detailed 4 
assessment of the electrophysiological effects of new drugs and, unless justification can be 5 
provided, human studies assessing effects on the QT interval.(6) This makes it less likely 6 
that unexpected TdP will occur after drugs are marketed, such as occurred previously for 7 
several drugs such as probucol, terfenadine, astemizole, grepafloxacin, thioridazine and 8 
cisapride. It does however increase the cost of drug development and the chance of late 9 
failure of a novel drug to proceed to market.  10 
Many episodes of TdP might be avoided by more skilful prescribing and monitoring of QT 11 
prolonging therapy. The benefit-risk balance of drug use should be considered on an 12 
individualised basis, taking into account the patient’s medical history, baseline ECG and 13 
blood test results. This is challenging for prescribers as the risks associated with such 14 
patient factors are not clearly defined. When a QT prolonging drug is needed, the lowest 15 
effective dose should be used and the drug should be discontinued when no longer required. 16 
It may be difficult for prescribers to find information about the propensity of drugs to prolong 17 
the QT interval or cause TdP, but frequently updated information is available, for example 18 
from the CredibleMeds website.(18) 19 
Drug interactions are important precipitants of torsades and avoiding these is essential. 20 
These may be pharmacokinetic, for example via inhibition of metabolism (Table 2), or 21 
pharmacodynamic, where for example two QT prolonging drugs are used together. There 22 
are numerous clinical examples of TdP occurring after interactions of both main categories. 23 
(19)  24 
It is important to have access to an ECG in all patients receiving drugs that may prolong the 25 
QT interval. Depending upon the clinical and individual circumstances and the risk 26 
  
8 
associated with the drug being used, it may be appropriate to perform baseline ECGs and 1 
blood tests before prescribing and repeating these after dose increases, with co-prescription 2 
of drugs that may interact or during times of intercurrent illness. Useful advice on risks and 3 
the need for ECG monitoring may be found in the drug’s summary of product characteristics. 4 
Monitoring potassium, magnesium and calcium concentrations is particularly important if 5 
there are clinical reasons for concern, for example with gastrointestinal disturbances or 6 
institution of diuretic therapy. 7 
 8 
MANAGEMENT 9 
The American College of Cardiology (ACC), American Heart Association (AHA) and 10 
European Society for Cardiology ESC) published guidelines for management of ventricular 11 
arrhythmias, including drug-induced TdP, in 2006.(20) and the key recommendations have 12 
been endorsed in a more recent ACC/AHA statement.(9) 13 
QT prolongation without torsade 14 
There remains considerable variation in practice in the management of patients with 15 
clinically important QT prolongation (e.g. above the nomogram at-risk line) in the absence of 16 
observed episodes of TdP. If feasible, the predicating drug should be discontinued and other 17 
modifiable risk factors addressed, including correction of oxygen saturation and plasma 18 
potassium, calcium and magnesium, concentrations as necessary. Potassium administration 19 
to achieve a concentration between 4.7 and 5.2 mmol/L has been shown to shorten QT 20 
interval and reduce QT dispersion in human volunteers administered quinidine.(21)  21 
Patients with clinically important QT prolongation should undergo continuous ECG 22 
monitoring; the QT interval on the 12 lead ECG should be re-evaluated periodically, with the 23 
frequency depending on the clinical circumstances and the extent of QT prolongation.  24 
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Some clinicians administer intravenous magnesium sulphate to patients with QT 1 
prolongation in the absence of TdP,(3) but this is probably unnecessary unless multiple risk 2 
factors are present and especially if ECG features suggest instability, such as frequent 3 
premature contractions or unstable T/U intervals. Although risks from magnesium 4 
administration are small, the risk of harm from TdP is also low in appropriately monitored 5 
hospitalised patients with isolated aLQTS and there is currently no evidence of benefit. 6 
Because magnesium does not affect the QT interval, it is not possible to measure response. 7 
Torsades de pointes 8 
Prolonged episodes of continuous TdP associated with severe hypotension or cardiac arrest 9 
should be terminated by electrical cardioversion.(9) It is more typical, however, for TdP to 10 
occur in recurrent self-terminating bursts. Under these circumstances treatment is directed at 11 
stabilising the myocardium using magnesium sulphate and by shortening repolarisation by 12 
increasing heart rate using chronotropic drugs such as isoproterenol (isoprenaline) or 13 
cardiac pacing.(20) Benefit may also be obtained using antiarrhythmic drugs, although some 14 
of these, especially class 1a and class 3 agents, may worsen the arrhythmia. 15 
As for isolated QT prolongation, responsible agent(s) should be discontinued and modifiable 16 
risk factors such as hypokalaemia, hypomagnesaemia and hypoxia should be addressed. 17 
Several sources recommend that serum potassium is maintained in the high normal range 18 
(4.5-5.0 mmol/L), although evidence is limited.(9, 20)   19 
Magnesium sulphate 20 
Administration of magnesium sulphate is currently recommended as immediate first line 21 
treatment for torsades de pointes.(20)  The mechanism for benefit is uncertain,(9) but 22 
magnesium may reduce the amplitude of EADs by inhibiting the late calcium influx via L-type 23 
calcium channels that is associated with delayed ventricular repolarisation. As a result, 24 
EADs are less likely to reach threshold potential and provoke or sustain TdP.(22) As a co-25 
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factor for the sodium potassium ATPase, magnesium may stabilise the membrane potential 1 
by facilitating potassium influx, correcting dispersed repolarisation without shortening the 2 
action potential duration. Efficacy has not been demonstrated in a randomised controlled 3 
trial, but in a case series of 12 adult patients with TdP (in 9 induced by antiarrhythmic drugs) 4 
a single 2g (8 mmol) dose of magnesium sulphate administered intravenously over 1-2 5 
minutes caused resolution in 9 patients, with a second dose being effective in the remaining 6 
3, without reducing the QT interval.(23) Similar results were reported from a French study, 7 
where TdP was completely abolished after administration of intravenous magnesium 1-3 g in 8 
4 of 6 patients. In the remaining 2 patients, TdP improved but recurred in one and was 9 
suppressed only partially in the other.(24) An initial intravenous bolus of 2.3-12 mg/kg 10 
magnesium sulphate gave a complete response in 5 of 6 children with congenital or acquired 11 
LQTS, including both of the children with acquired LQTS. The serum magnesium 12 
concentration was 3.9 +/- 1.0 mg/dL (1.60 +/- 0.4 mmol/L) with a range of 2.9-5.4 mg/dL 13 
(1.2-2.2 mmol/L) immediately after bolus injection. (25) 14 
Magnesium therapy is simple and relatively safe to administer. Recommended doses in the 15 
UK are shown in Table 3. The most prominent adverse effect is flushing, but nausea and 16 
vomiting, hypotension, and drowsiness can occur, especially with higher doses. Substantial 17 
hypermagnesaemia may cause confusion, slurred speech, double vision, neuromuscular 18 
blockade, respiratory depression, hypophosphatemia, hyperosmolar dehydration, cardiac 19 
arrhythmias, coma and cardiac arrest.  Severe toxicity is usually encountered with 20 
concentrations >3.5 mmol/L. 21 
Isoproterenol 22 
Isoproterenol (isoprenaline) increases the heart rate due to non-selective beta1/beta2 23 
adrenoceptor agonist actions; this shortens the QT interval and effective refractory period. In 24 
a dog model, isoproterenol prevented quinine-induced TdP. (26, 27) There are no 25 
randomised controlled trials of isoproterenol use for TdP in humans, but occasional case 26 
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reports suggest benefit.(28) It is probably particularly useful as a bridge to temporary pacing 1 
in patients unresponsive to magnesium sulphate. Dose recommendations are shown in 2 
Table 3. Isoproterenol may, however, be contraindicated in congenital LQTS as it may 3 
prolong QT interval and induce early afterdepolarisations (29) and may also enhance 4 
dispersion of repolarisation in some subtypes.(30) It may also worsen ventricular tachycardia 5 
if this is not TdP. Other adverse effects include palpitations and flushes and worsening of 6 
cardiac ischaemia or hypertension.  7 
Atropine is an alternative pharmacological method for increasing heart rate. It not only 8 
increases heart rate but also supresses QT prolongation and TdP induced by intracoronary 9 
acetyl choline in patients with cLQTS. (31)  Although atropine has been used to for treatment 10 
of TdP,(32) it is not usually recommended as it can induce paradoxical bradycardia with 11 
consequent worsening of the arrhythmia.(33) 12 
Pacing 13 
Transvenous pacing increases the heart rate, prevents pauses and can suppress or abolish 14 
episodes of TdP. Animal models indicate efficacy for pacing in dofetilide-induced  15 
torsade,(34) although in a dog model atrial pacing was relatively ineffective at preventing 16 
quinidine-induced torsade.(27) Case reports and case series in humans have suggested 17 
benefits from pacing for treating TdP induced by quinidine, disopyramide,(35) sotalol (36) or  18 
amitriptyline(37), including in patients unresponsive to magnesium sulphate.(38)  Evidence 19 
suggests that pacing rates of at least 70/min are required; (39) typically rates of 100 to 110 20 
/min are used, while occasionally rates of up to 140 / min may be needed. (38, 40) Pacing is 21 
generally considered as an option after magnesium sulphate. Its efficacy in comparison to 22 
isoproterenol is uncertain, but it may be a better option when the risk of torsade may persist 23 
over longer periods, for example with longer acting precipitant drugs. 24 
 25 
26 
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Antiarrhythmic drugs 1 
Few patients experiencing TdP fail to respond to the steps described above, and use of 2 
conventional antiarrhythmic drugs is rarely required. Those that prolong repolarisation, the 3 
class 1a or III drugs, may in theory worsen TdP and should be avoided. There is, however, 4 
limited evidence of benefit from use of class 1b agents. Lidocaine was effective in dog (27) 5 
and rabbit (41) models of TdP and there are  case reports of benefit for treating TdP in 6 
humans.(42, 43) Phenytoin has also been reported to be successful in case reports.(28, 44)  7 
Novel approaches 8 
Several drugs are in development to enhance delayed rectifier conductance and these may 9 
have future value for treatment of aLQTS. One of these, NS1643, supressed dofetilide-10 
induced QT prolongation and TdP in a rabbit model.(45) Activators of cardiac ATP-sensitive 11 
potassium channels (KATP) such as pinacidil and cromakalim have also had beneficial effects 12 
for aLQTS associated with some but not all culprit drugs.(46) 13 
Alpha-2 adrenoceptor agonists attenuate L-type calcium channels and supress EADs. 14 
Promising results were obtained for clonidine and dexmedetomidine, with both drugs 15 
shortening the QT interval and reducing the incidence of TdP in a rabbit model of aLQTS. 16 
(47) 17 
The anti-ischaemic agent ranolazine blocks the late sodium current which is responsible for 18 
prolonging action potential duration and which also makes a contribution to EADs and has 19 
been shown to prevent or terminate clofilium-induced TdP in rabbits. It may, however, 20 
prolong action potential duration and QT interval at higher concentrations due to Ikr 21 
blockade. (41) 22 
EADs are facilitated by protein kinases and there is limited evidence that kinase inhibition 23 
may be a viable antiarrhythmic strategy, reducing inducibility of TdP.(48) 24 
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Aftercare 1 
In patients with aLQTS, the risk of further episodes of TdP is substantially reduced once 2 
precipitants and/or culprit agent have been removed and this should result in normalisation 3 
of the QTc interval. If it does not, further evaluation to exclude cLQTS should be considered, 4 
including obtaining a family history focusing on syncope, epilepsy and/or sudden death. 5 
Cardiological and genetic evaluation will then be required for patients to confirm evidence for 6 
the condition and for the family members of those in whom cLQTS is confirmed.(49) 7 
In view of the widespread use of QT prolonging drugs, it is important that these are not 8 
prescribed inadvertently to patients who have previously experienced TdP, as the risk of 9 
further episodes would be high. (50) Patients and their primary clinicians should be alerted to 10 
this risk and to available sources of information about these drugs.(18) 11 
12 
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TABLE 1. Examples of currently marketed drugs that have been associated with torsade de 2 
pointes 3 
 4 
Antiarrhythmics 
Class Ia 
 
Class Ic 
Class III 
 
Quinidine  
Disopyramide  
Flecainide 
Amiodarone  
Dofetilide  
Dronedarone  
Ibutilide  
Sotalol  
 
Antipsychotics Haloperidol 
Pimozide 
Thioridazine 
Chlorpromazine 
Amisulpride 
 
Anaesthetics 
 
Sevoflurane 
Propofol 
 
Antidepressants 
 
Citalopram 
Escitalopram 
Amitriptyline 
 
Antimalarials Chloroquine 
Halofantrine 
 
Anticancer 
 
Arsenic trioxide 
Vandetanib 
Sunitinib 
 
Antimicrobials 
 
Macrolides 
 
 
Quinolones 
 
Others 
 
 
 
 
Azithromycin 
Clarithromycin 
Erythromycin 
Levofloxacin 
Moxifloxacin 
Pentamidine 
Fluconazole 
Ketoconazole 
HIV 
 
Others 
 
Cocaine 
Methadone  
Ondansetron  
Domperidone  
Anagrelide 
Donepezil 
Cilostazol 
 
5 
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TABLE 2. Examples of potential pharmacokinetic interactions affecting drugs that prolong 1 
the QT interval, inhibit cytochrome P450 (CYP) inhibitors, or both.   2 
 3 
 CYP isoform affected 
  CYP1A2 CYP2D6 CYP3A4 
QT 
prolonging 
drugs 
Haloperidol 
Amitriptyline 
Imipramine 
Amitriptyline 
Haloperidol 
Imipramine 
Quinidine 
Erythromycin 
SSRIsϯ 
Amiodarone 
Cisapride 
Haloperidol 
Quinidine 
Pimozide 
Methadone 
 
CYP 
inhibitors 
Flouroquinolones* 
Cimetidine 
Amiodarone* 
Grapefruit juice 
Ritonavir 
SSRIs* 
Amiodarone* 
Quinidine* 
Methadone* 
Protease inhibitors  
Imidazole fungicides* 
Diltiazem 
SSRIsϯ* 
Erythromycin* 
Grapefruit juice 
 
*May also prolong QT interval 4 
ϯSelective serotonin reuptake inhibitors 5 
 6 
7 
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TABLE 3. Drugs used for treating torsades   1 
 2 
 Dose (adult) Notes 
Magnesium sulphate Adults - 2 g* (8 mmol)  
Children - 25-50 mg/kg* (0.1-0.2 
mmol/kg) to maximum of 2 g. 
 
Give as IV infusion over 10-15 minutes  
Measure plasma magnesium after 
administration 
Repeated doses may be needed 
Isoproterenol Adults - 0.5-5 mcg/min  
Children – 0.1-1.0 mcg/kg/min 
Give as continuous IV infusion 
An initial bolus of 20-60 mcg may be used 
in adults (0.3-1 mcg/kg in children)  
Titrate infusion rate to heart rate of 90-
110. Higher heart rates may be used if 
torsades recurs. 
*Magnesium sulphate heptahydrate3 
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Figure 1. QT interval nomogram for determining ‘at risk’ QT-Heart rate pairs from a single 1 
12-lead ECG. Reproduced from reference (11), with permission. 2 
 3 
 4 
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